Nilvadipine - Archer Pharmaceuticals

Drug Profile

Nilvadipine - Archer Pharmaceuticals

Alternative Names: ARC 029

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Archer Pharmaceuticals
  • Class Antidementias; Antihypertensives; Dihydropyridines; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 10 Feb 2016 Nilvadipine is still in phase III trial for Alzheimer's Disease (In adults, In elderly) in France, Germany, Greece, Hungary, Ireland, Italy, Sweden, United Kingdom and the Netherlands (NCT02017340)
  • 30 Jan 2014 No development reported - Phase-I for Alzheimer's disease in USA (PO)
  • 31 Oct 2012 Phase-III clinical trials in Alzheimer's disease (In adults, In elderly) in United Kingdom, Sweden, Netherlands, Italy, Ireland, Hungary, Greece, Germany, France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top